

May 29, 2026

BSE Limited

Phiroze Jeejeebhoy Towers, Dalal
Street, Fort,
Mumbai – 400001, Maharashtra
Scrip Code – 544709

ISIN: INE0P8B01020

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400051, Maharashtra
Symbol – GAUDIUMIVF

ISIN: INE0P8B01020

Dear Sir/Madam,

Subject: Investor Presentation on the Financial Results of the Company for the quarter and year ended March 31, 2026

Pursuant to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Investor Presentation on highlights of the Financial Results of the Company for the quarter and year ended March 31, 2026.

This above information will also be hosted on the website of the Company.

Kindly take the information on record.

Thanking you.

For and on behalf of Gaudium IVF and Women Health Limited

(Formerly known as Gaudium IVF and Women Health Private Limited)

Naveen Kumar

Company Secretary and Compliance Officer

Membership No.: A69788

Encl.: a/a





GAUDIUM IVF
& WOMEN HEALTH LTD.

INVESTOR PRESENTATION
Q4 & FY26



Safe Harbour

This document is prepared only for information purpose and do not solicit/recommend/guide for any Investment/Buy-Sell in any financial instrument of **Gaudium IVF and Women Health Limited (“Gaudium”)** and/or any of its subsidiary company or associate company. Neither **Gaudium** nor any of its group company/subsidiary Company/ associate company , directors, or employees related person are responsible for any gains/loss arising to any person/body corporate due to any such transaction as stated above.

This document may contain certain forward-looking statements. These forward-looking statements can generally be identified by words or phrases such as “aim”, “anticipate”, “believe”, “expect”, “estimate”, “intend”, “objective”, “plan”, “project”, “shall”, “will”, “will continue”, “will pursue” or other words or phrases of similar meaning. Similarly, statements that describe strategies, objectives, plans or goals are also forward-looking statements. **Gaudium** cannot assure investors that the expectation reflected in these forward-looking statements will prove to be correct. Given these uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and not to regard such statements as a guarantee of future performance.

Table of Contents

01

About Us

- Company at a Glance
- Journey of Gaudium IVF
- Process Flow - IVF Treatment
- AI-Powered End-to-End Fertility Solutions
- Key Clinical Highlights
- Strategic Milestones

02

Business Overview

- IVF Industry Overview
- Growth Drivers in the Industry
- Entry Barriers in Industry
- Our Moat, Our Momentum
- Pan-India Presence
- Serving Patients Around The Globe
- Center/Hub Wise Details
- AI That Makes the Difference
- Infrastructure & Facilities at Centers
- 360° Customer Acquisition
- Rapid Growth Strategy
- Board Of Directors

03

Q4 & FY26 Financial Performance

- Key Ratios & Cash Flows (Consolidated)
- Standalone Financial Statement
- Consolidated Financial Statement

04

Annexures

- Case Studies
- Awards and Recognitions
- CSR Initiatives
- Patient Testimonials



ABOUT US

Board Of Directors



Dr. Manika Khanna,
Promoter & CMD

Holds an **MBBS (Gold Medallist)** and **MD in Obstetrics & Gynecology** from Maharaja Sayajirao University of Baroda. She has completed training in **Advanced Gynecological Endoscopic Surgery** in **Kiel, Germany**, and in advanced gynecological endoscopy from Melbourne IVF Gujarat Private Limited. She brings over 16 years of experience in IVF treatment.

Awards: Delhi Ratna Award (2008) and the Women Excellence Award (2016).



Mr. Vishad Khanna
Director



Mr. Rajesh C. Bhojani
Independent Director



Dr. Peeyush Khanna,
Promoter & WTD

Holds an MBBS from Manipal Academy of Higher Education and a Diploma in Child Health from University of Delhi (1999) and has been associated with Gaudium since its incorporation and brings over **10 years of experience in pediatrics and child health.**

He currently leads the **Pediatric Division** and supports the Company's operations across India.

Awards: Secretary Appreciation Award from the Delhi Medical Association (2016), the Organizer Award at the Pediatric Conference of North India (2015), Recognize the Genius' award (2021)



Mr. Brajesh S Bhadauria
Independent Director




Mr. Suresh Marpu
Independent Director

Company at a Glance

Founded: March 2015 by Dr Manika Khanna and Dr. Peeyush Khanna

Network: **7 Hubs + 28 Spokes** | Presence: **9 States across India**

Services Revenue Split



AI Initiatives to help improve success rate: SiD & ERICA

Success Rates:

First Attempt - **58%**


Success Rates:

Multiple Attempts - **85%**

No of OPU: **2,255**


Average Revenue Per Patient: **Rs. 2,97,998**

Journey of Gaudium IVF



Process Flow - IVF Treatment

A seamless, patient-centric journey supported by clinical excellence and care at every step




AI-Powered End-to-End Fertility Solutions




Advanced IVF
Treatment




Male Infertility



Ovulation
Induction




Egg Freezing



ERICA




SiD



Infertility
Surgeries



Frozen Embryo
Transfer



Embryo
Freezing



Gynae
Consultation



Laparoscopy
for
Infertility



PCOD/PCOS

BUSINESS OVERVIEW




IVF Industry Overview


Strong demographic tailwinds, significant treatment gap and evolving industry structure create a long runway for scalable growth


MARKET SIZE & GROWTH

India IVF Market Size (USD Billion)




 Global IVF market projected to grow from USD 27.49Bn to USD 54.60Bn at ~7.1% CAGR


 India's share in the global IVF market expected to increase from ~4.8% to ~8.3%


 India remains among the **fastest-growing IVF markets globally**, outpacing developed markets

SIGNIFICANT UNDERPENETRATION

Huge gap between need and treatment




 Indicates **<2%** penetration of addressable demand


 Only **~1 in 50** couples who require IVF currently access treatment

STRUCTURAL SUPPLY GAP

IVF access remains concentrated in **Top 8 Metro cities**
Delhi NCR, Mumbai, Ahmedabad, Chennai, Kolkata, Hyderabad, Bengaluru, Pune



 Industry transitioning from **fragmented standalone clinics** to organized platforms

 Regulatory tightening (ART Act) accelerating shift towards **compliant, scalable players**

Growth Drivers in the Industry



DECLINING FERTILITY RATES

- India's fertility rate has fallen below replacement levels, indicating structural demand
- Continued decline expected, increasing reliance on assisted reproductive treatments



DELAYED PARENTHOOD

- Rising age at marriage and first childbirth, particularly in urban India
- Increasing number of patients seeking fertility treatment post age 30–35



LIFESTYLE & HEALTH FACTORS

- Rising incidence of PCOS, obesity, stress, and hormonal disorders
- Male infertility contributes to ~50% of overall cases



IMPROVING AWARENESS & ACCEPTANCE

- Growing awareness and reduced stigma around IVF treatment
- Increased adoption driven by digital outreach and social normalization



TECHNOLOGY-DRIVEN OUTCOMES

- Advancements in AI-enabled embryo selection, genetic testing, and cryopreservation
- Improving success rates, patient conversion, and confidence via AI-driven technology integration



MEDICAL TOURISM ADVANTAGE


- IVF treatment in India costs ~70–80% lower than developed markets
- Positioning India as a global destination for fertility treatment



REGULATORY TAILWIND

- ART Act driving standardization, transparency, and compliance
- Accelerating consolidation in favour of organized players

Entry Barriers in Industry



Navigating Key Industry Barriers




Built a Scalable Fertility Platform


Every barrier above is a moat Gaudium IVF already crossed positioning the company as a category leader with sustainable competitive advantage.

Our Moat, Our Momentum


Eleven strengths built over **15+ years** that create a compounding advantage for Gaudium IVF



Pan-India Presence



Serving Patients Around The Globe

 Delivering world – class fertility care to patients across the globe



Infrastructure & Facilities at Centers



Clinical Facilities

- **Consultation rooms** for patient and doctor engagement for preliminary examination
- Advanced andrology lab equipped for **semen analysis and sperm processing.**
- **Embryology lab** for egg fertilization, embryo culture, and embryo transfer
- **Surgical suite** for egg retrieval and embryo transfer



Specialized Equipment's

- **Incubators** to help embryos grow and develop properly during the IVF process
- **Laminar flow hoods** to protect against dust and other particles, making it safer for handling eggs and embryos.
- **Centrifuge** to maintain the temperature and keep semen and embryos safe from dust and airborne germs.
- **A cryo storage tank** is used to **freeze and store fertilized eggs**

Key Clinical Highlights

SOP-Driven Organization

From clinical, embryology and doctors to housekeeping.

AI-Powered IVF

First in India, 2nd outside the US to introduce AI tools SID & ERICA.

In-House Trained Talent

Clinicians and embryologists trained within Gaudium.

Constant Innovation

Especially for patients with multiple failed IVFs.

Signature Labs & IVF

State-of-the-art Gaudium Signature laboratories and IVF.

MANTRANA

Dedicated emotional counselling support for patients.

ART Law Compliance

Strict adherence to the ART (Regulation) Act.

Global Patient Base

Successfully treated patients from 30+ countries.

58%

Success rate at one attempt; early results show an 8–9% increase with SID & ERICA.



Strategic Milestones

India's First

IVF company to be listed on the stock market, marking a historic milestone in the fertility care industry.

India's No. 1

IVF Clinic ranking as per the Health Survey conducted by Times of India.

India's First

IVF chain to introduce Artificial Intelligence in infertility treatment.

India's First

IVF company to receive the European Quality Award for the highest quality standard.

AI That Makes the Difference

Gaudium is among the few IVF providers in India to deploy both SiD and ERICA, creating an integrated AI-assisted clinical workflow that supports improved outcomes and consistent success across centres.


SiD

AI POWERED SPERM SELECTION

Selecting the best sperm for fertilisation (ICSI)

How It Works

- Analyses sperm in real time using AI-based imaging
- Evaluates key parameters including motility and movement patterns
- Assigns an objective score to each sperm
- Enables selection of the highest-quality sperm with greater consistency



Why It Matters

- Reduces subjectivity in sperm selection
- Improves fertilisation and embryo quality
- Ensures consistency across centres


ERiCA

ERICA

AI Powered embryos based on implantation


How It Works

- Analyses embryo images using advanced algorithms
- Evaluates multiple developmental parameters
- Identifies features not visible to the human eye
- Classifies embryos based on implantation potential



Why It Matters

- Improves embryo selection accuracy
- Supports better clinical outcomes
- Reduces reliance on additional invasive testing



The Integrated AI Advantage



Higher Success Rates
Better selection leads to improved outcomes



Standardised Outcomes
Reduced variability across centres



Reduced Subjectivity
Data-driven decision making at critical stages




Scalable Clinical Quality
Enables expansion without compromising outcomes




Sustainable Technology Advantage
Integrated AI systems support long-term differentiation

360° Customer Acquisition



Rapid Growth Strategy



FY27

3 out of 10 | **2** In Delhi/NCR | **1** In Nagpur
Hubs Launching Soon

FY28

8 new centers

FY29

1 new center

The addition of **new centers** will enhance Gaudium IVF's **pan-India brand visibility**

Increased **customer footfall** is expected to drive higher **revenues and strengthen key financial parameters**

This expansion will **position Gaudium IVF** among the leading large players in the industry

Center/Hub Wise Details

Center Wise Details							
Particulars	Delhi - Janakpuri	Delhi - Greater Kailash	Ludhiana	Patna	Mumbai	Bengaluru	Srinagar
State	Delhi NCR	Delhi NCR	Punjab	Bihar	Maharashtra	Karnataka	Jammu & Kashmir
Date of Commencement	2009*	2016*	2017#	2019*	2022	2023	2024
Owned/Rental	Rental						
No of Beds	15	3	5	5	9	7	7
No of OT	1	1	1	1	1	1	1
IVF Facility	Yes	Yes	Yes	Yes	Yes	Yes	Yes
ART Level	Level-2	Level-1	Level-2	Level-2	Level-2	Level-2	Level-2

**Gaudium IVF and Gynae Solutions, a proprietary firm of Dr. Manika Khanna, was acquired by the company in accordance with the main object clause as mentioned in the Memorandum of Association.*

Pursuant to Slump Sale Agreement dated February 02, 2023, executed among Gaudium IVF and Women Health Private Limited (the Purchaser), Gaudium Bawa IVF (the Partnership Firm), Dr. Manika Khanna (Partner 1), Dr. Sayesha Bawa (Partner 2), and Gaudium IVF and Women Health Private Limited (Partner 3), the company acquired the business of Gaudium Bawa IVF.



Q4 & FY26 FINANCIAL PERFORMANCE

Key Ratios & Cash Flows (Consolidated)


Ratio	FY25	FY26
EBITDA Margin	40.48%	36.13%
EBIT Margin	37.92%	34.20%
EBT Margin	35.95%	30.85%
PAT Margin	27.12%	23.47%
Debt / Equity	0.45	0.16*
RoE Average	52.34%	24.66%*
RoCE Average	65.54%	34.80%*
Cash Flows (Rs in Lakhs)		
Cash Flow Generated from/(Used in) Operating Activities	871.77	724.72
Cash Flow from/(Used in) Investing Activities	(1,517.43)	(8,765.41)
Cash Flow from/(Used in) Financing Activities	181.66	8,197.76
Net Increase/(Decrease) in Cash and Cash Equivalents	(464.00)	157.07
Opening Cash and Cash Equivalents	1,185.50	721.50
Closing Cash and Cash Equivalents	721.50	878.57

***Note:**


FY26 ROE, ROCE, and Debt/Equity ratios reflect the impact of Rs. 90 Cr fresh equity infusion through the IPO (listed February 27, 2026).
 Margin and Return Ratios are based on PAT from Continuing Operations.

Financial Snapshot


Revenue From Operations (Rs. Lakhs)




Operating EBITDA (Rs. in Lakhs)



PAT (Rs. in Lakhs)



PAT Margin



***Note:** Margin Ratios are based on PAT from Continuing Operations.

Financial Statement (Rs. Lakhs) Standalone

Income statement	Q4 FY26	Q4 FY25	YOY	Q3 FY26	QOQ	FY26	FY25	YOY
Revenue from Operations	2,216.60	1,682.29	31.76%	1,419.35	56.17%	7,157.85	5,900.16	21.32%
EBITDA (Ex. Other Income)	1,126.15	828.13	35.99%	583.21	93.10%	3,456.59	2,786.43	24.05%
<i>EBITDA Margins %</i>	50.81%	49.23%	158 bps	41.09%	972 bps	48.29%	47.23%	106 bps
PAT	773.14	620.92	24.51%	318.40	142.82%	2,228.77	1,863.38	19.61%
<i>PAT Margins %</i>	34.88%	36.91%	(203) bps	22.43%	1,245 bps	31.14%	31.58%	(44) bps

Comments:

Gaudium's standalone core IVF Treatment business continued to anchor the financial performance during FY26, supported by strong operating leverage and consistently high clinical success rates.

Financial Statement (Rs. Lakhs) Standalone

Balance Sheet	FY25	FY26	Balance Sheet	FY25	FY26
Equity Share Capital	3,069.72	3,639.34	Non-Current Assets		
Other Equity	1,473.61	11,287.14	Property, Plant and Equipment	618.50	534.67
Net Worth	4,543.33	14,926.47	Right of Use Asset	146.11	121.62
Non-Current Liabilities			Goodwill	13.82	13.82
Borrowings	172.73	-	Other Intangible Assets	988.41	865.28
Lease Liabilities	149.54	128.26	Intangible Assets Under Development	738.32	1,196.83
Others	98.13	95.63	Others	1,045.80	9,138.08
Current Liabilities			Current Assets		
Borrowings	1,720.71	2,109.95	Inventories	254.46	229.86
Lease Liabilities	17.92	21.28	Trade Receivables	2,367.66	4,260.42
Trade payables	170.37	283.25	Cash and Cash Equivalents	672.83	853.69
Others	624.84	293.74	Others	651.66	644.32
Total Source of Funds	7,497.57	17,858.59	Application of Funds	7,497.57	17,858.59

Cash Flows (Rs in Lakhs)	FY25	FY26
Cash Flow Generated from/(Used in) Operating Activities	843.64	727.34
Cash Flow from/(Used in) Investing Activities	(1,517.01)	(8,564.23)
Cash Flow from/(Used in) Financing Activities	181.66	8,017.74
Net Increase/(Decrease) in Cash and Cash Equivalents	(491.70)	180.86
Opening Cash and Cash Equivalents	1,164.54	672.83
Closing Cash and Cash Equivalents	672.83	853.69

Financial Statement (Rs. Lakhs) Consolidated

Income statement	Q4 FY26	Q4 FY25	YOY	Q3 FY26	QOQ	FY26	FY25	YOY
Revenue from Operations	3,035.11	2,692.43	12.74%	2,450.70	23.85%	10,435.70	7,072.40	47.56%
EBITDA (Ex. Other Income)	1,217.20	872.18	39.56%	655.08	85.81%	3,770.40	2,863.07	31.69%
<i>EBITDA Margins %</i>	40.10%	32.39%	771 bps	26.73%	1,337 bps	36.13%	40.48%	(435) bps
PAT (Continuing Operations)	835.74	645.55	29.46%	363.05	130.20%	2,448.85	1,917.73	27.69%
<i>PAT Margins %</i>	27.54%	23.98%	356 bps	14.81%	1,273 bps	23.47%	27.12%	(365) bps

Comments:

Gaudium's consolidated revenue growth was driven by higher patient volumes across mature hubs, supported by strong clinical outcomes, while margins benefited from operating leverage and improved scale efficiencies.

Financial Statement (Rs. Lakhs) Consolidated

Balance Sheet	FY25	FY26	Balance Sheet	FY25	FY26
Equity Share Capital	3,069.72	3,639.34	Non-Current Assets		
Other Equity	1,560.02	11,590.87	Property, Plant and Equipment	640.90	746.44
Net Worth	4,629.74	15,230.22	Right of Use Asset	146.11	121.62
Non-Current Liabilities			Goodwill	37.00	37.00
Borrowings	172.73	-	Other Intangible Assets	988.40	865.28
Lease Liabilities	149.54	128.26	Intangible Assets Under Development	738.50	1,196.83
Others	98.18	99.25	Others	919.80	9,013.08
Current Liabilities			Current Assets		
Borrowings	1,720.71	2,307.48	Inventories	722.95	354.46
Lease Liabilities	17.92	21.28	Trade Receivables	3,286.72	5,337.93
Trade payables	1,395.1	1,222.92	Cash and Cash Equivalents	721.50	878.57
Others	667.35	301.05	Others	649.39	759.24
Total Source of Funds	8,851.27	19,310.45	Application of Funds	8,851.27	19,310.45
Cash Flows (Rs. in Lakhs)			FY25	FY26	
Cash Flow Generated from/(Used in) Operating Activities			871.77	724.72	
Cash Flow from/(Used in) Investing Activities			(1,517.43)	(8,765.41)	
Cash Flow from/(Used in) Financing Activities			181.66	8,197.76	
Net Increase/(Decrease) in Cash and Cash Equivalents			(464.00)	157.07	
Opening Cash and Cash Equivalents			1,185.50	721.50	
Closing Cash and Cash Equivalents			721.50	878.57	

ANNEXURES



Case Studies - Our Amazing Successes



10

Remarkable Journeys

Real outcomes achieved
against the toughest odds,
with science & care

- **2009 – A Historic First:** 51-year-old achieved a successful IVF & live birth with her own eggs.
- **2012 – 15 Failed IVFs:** 15 prior failures (5 USA, 5 Delhi, 5 Mumbai); conceived & widely covered by media.
- **2020 – Surrogacy Success:** A well-known Bollywood actress with APLA syndrome became a mother via surrogacy.
- **Guinea – Complex Case:** 42-year-old with hypertension, diabetes & multiple fibroids achieved motherhood.
- **USA – Via US Embassy:** 5 prior IVFs & 6 miscarriages — her miracle baby at Gaudium.
- **IVIG Therapy Breakthrough:** 8 prior losses; first live birth through innovative IVIG therapy.
- **NRI Couple – 12 Failures:** Success on the 3rd attempt — later a 2nd baby from frozen gametes.
- **1 KG Fibroid:** A successful IVF cycle & live birth with a one-kilogram fibroid.
- **48 & Nine Failures:** Nine prior failed cycles elsewhere; a healthy daughter from frozen eggs.
- **Morbidly Obese – First Try:** A successful self-cycle on the very first attempt.

Most Awarded IVF Chain in India



India's Most Powerful Symbol of brand Excellence by Power Brand in London, UK



India best Practice Award: IVF Chain of the Year 2019 by Frost & Sullivan (USA)



IVF Leader of the Year, India 2023 Award by Gurudev Sri Sri Ravishankar



Former President of India Smt. Praibha Pail for her outstanding work in the field of infertility



India best Practice Award: IVF Chain of the Year 2019 by Frost & Sullivan (USA)



Highly Presigious Civilian Award "Service of Bharat in the field of Health" by Shri Mansukh Madaviya (Hon'ble Union Minister for Health & Fdamily Welfare



Ranked No. 1 Health Survey Conducted by Times of India



Winner of healthcare brand by Shri S.P. Singh Baghel: Minister of State of Health and Family welfare



European Quality Award by ESQR, Spain 2022



Medical Service Award from Honourable Health Minister of Delhi Sh. Saurabh Bhardwaj

Additional Recognition Over the Years

● 2021

Oxford Academy, UK

Name in Medical Science — Global Women's Health

● 2017

Times Healthcare Achievers

Rising Stars O&G — Best Speciality Centre

● 2017

BusinessWorld Awards

Healthcare Personality of the Year – Women

● 2016

Indian Medical Association

Chikitsa Ratan Award

● 2016

URS AsiaOne

World's Greatest Leaders in Healthcare

● 2016

Delhi Medical Association

Women Achiever of the Year

● 2015

National Healthcare Achievers

Best IVF & Surrogacy Hospital 2015–16

● 2014

Healthcare Leadership Summit

Best Single-Speciality Hospital - IVF

○ 2013

IVF India Magazine

Best IVF Institute in India

CSR Initiative



Ladli Foundation Trust
A National Award Winning
Non-Profit Organization

Ladli Shiksha & Swasthya Initiative

Empowering adolescent girls from underserved communities through education access, health literacy and life-skills development - helping build informed choices, stronger confidence and resilient futures.



2,500+
Students Reached



4 Govt. Schools
Covered



11–18 Years
Target Age Group



**EWS & Marginalized
Communities**
Primary Beneficiary Group



Delhi
Project Location



Our 4 Key Interventions



Education Access: Provided educational support through school stationery kits aimed at improving classroom preparedness, participation and learning continuity.



Health & Menstrual Hygiene Awareness: Delivered structured MHM workshops through trained female educators focused on healthy practices, awareness and creating safe spaces for open dialogue.



Health Literacy & SRH Education: Conducted age-appropriate sessions covering reproductive health awareness, personal safety, bodily autonomy and informed decision-making.



Life Skills & Leadership Development: Implemented interactive competency-based modules focused on communication, confidence building, leadership and decision-making capabilities.



gaudium
babies

THANK YOU !

For further queries, Please contact:



Rakesh Kumar Sharma (CFO)
cfo@gaudiumivfcentre.com

For further queries, Please contact:



Rushabh Shah
rushabh.shah@adfactorspr.com
M: +91 8082180182

Anand Venugopal
anand.venugopal@adfactorspr.com
M: +91 7021852071

Naomi Fernandes
naomi.fernandes@adfactorspr.com
M: +91 70452 60278